BioXcel Therapeutics Reaches Nasdaq Listing Compliance Again After Brief Fall

BioXcel Therapeutics has regained compliance with Nasdaq's market value of listed securities requirement, having been notified on March 20, 2025, that its MVLS was below $35.0. The company's compliance status was regained, allowing it to continue listing on the exchange.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience, has successfully regained compliance with Nasdaq's market value of listed securities (MVLS) requirement. The company had previously been notified on March 20, 2025, that it was not in compliance with Nasdaq Listing Rule 5550(b)(2) because its MVLS was below $35.0 million for 30 consecutive business days BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements^[1].

Following a hearing before a Nasdaq Hearing Panel on May 1, 2025, BioXcel was granted an exception period to regain compliance. On September 17, 2025, Nasdaq confirmed the company's return to compliance with all Capital Market listing requirements, officially closing the matter BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements^[2]. The company now meets all Nasdaq Capital Market listing requirements for continued listing.

BioXcel Therapeutics is a biopharmaceutical company that utilizes artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, focuses on the development of medicines in immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements^[1].

The company's compliance status was regained, allowing it to continue listing on the exchange. This development is significant for investors, as it ensures the company's continued presence on the Nasdaq exchange, which can enhance liquidity and investor confidence.